BenevolentAI Past Earnings Performance
Past criteria checks 0/6
BenevolentAI's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 11.3% per year.
Key information
-13.5%
Earnings growth rate
125.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 11.3% |
| Return on equity | -67.2% |
| Net Margin | -863.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate
Dec 23
BenevolentAI S.A. (AMS:BAI) Analysts Just Trimmed Their Revenue Forecasts By 24%
Jun 22BenevolentAI S.A. (AMS:BAI) Analysts Just Cut Their EPS Forecasts Substantially
Apr 26BenevolentAI S.A. (AMS:BAI) Analysts Just Slashed This Year's Revenue Estimates By 20%
Apr 08Will BenevolentAI société anonyme (AMS:BAI) Spend Its Cash Wisely?
Dec 10We're Keeping An Eye On BenevolentAI société anonyme's (AMS:BAI) Cash Burn Rate
Jul 23Revenue & Expenses BreakdownBeta
How BenevolentAI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -63 | 23 | 57 |
| 30 Sep 23 | 9 | -61 | 19 | 64 |
| 30 Jun 23 | 11 | -59 | 14 | 70 |
| 31 Mar 23 | 11 | -112 | 69 | 71 |
| 31 Dec 22 | 11 | -164 | 125 | 72 |
| 30 Sep 22 | 9 | -186 | 141 | 69 |
| 30 Jun 22 | 8 | -208 | 157 | 66 |
| 31 Mar 22 | 6 | -158 | 106 | 61 |
| 31 Dec 21 | 5 | -108 | 56 | 57 |
| 31 Dec 20 | 7 | -55 | 52 | 20 |
| 31 Dec 19 | 5 | -48 | 41 | 21 |
| 31 Dec 18 | 7 | -27 | 40 | 0 |
Quality Earnings: BAI is currently unprofitable.
Growing Profit Margin: BAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAI is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare BAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: BAI has a negative Return on Equity (-67.16%), as it is currently unprofitable.